Key Advances in the Diagnosis and Treatment of Neuromyelitis Optic Spectrum Disorders



Release date

June 11, 2021

Last revision

May 27, 2021

Expiration date

June 11, 2022

Time to complete the activity

1.0 hour

Supplier declaration

This activity is provided by Paradigm Medical Communications, LLC.

Statement of support

Disclosure of commercial support

This activity is supported by an educational grant from Genentech, a member of the Roche group.

Target audience

This activity was designed to meet the educational needs of neurologists. It may also benefit neurological nurse practitioners and PAs; ophthalmologists; pharmacists; emergency medicine clinicians; and other healthcare professionals involved in the treatment of patients with Neuromyelitis Optic Spectrum Disorder (NMOSD).

Declaration of need

Making a rapid and correct diagnosis of NMOSD remains difficult, even after the discovery of disease-specific autoantibodies against aquaporin-4 (AQP4). The main symptoms of NMOSD are nonspecific, and some clinicians have confused the disease with multiple sclerosis (MS) or other disorders. Until recently, treatments to manage acute attacks and prevent future episodes were limited to off-label options such as azathioprine, mycophenolate, and rituximab. However, over the past 2 years, the therapeutic landscape has broadened significantly with the FDA approval of eculizumab, inbilizumab, and satralizumab. To improve patient outcomes, neurologists would benefit from ongoing education that keeps them abreast of treatment progress and best practices for making a timely and accurate NMOSD diagnosis.

Learning objectives

Upon successful completion of this activity, participants should be better able to:

  • Identify diagnostic clues that facilitate the differentiation of NMOSD from other autoimmune diseases, such as multiple sclerosis
  • Apply evidence-based strategies and clinical advice to optimize treatment selection for patients with NMOSD
  • Describe the mechanism of action of emerging and newly approved therapies indicated for NMOSD, along with associated safety and efficacy data


Andrew G. Lee, MD
Professor of ophthalmology, neurology and neurosurgery
Weill Cornell Medicine
President, Blanton Eye Institute
Houston, TX

Brian Gary Weinshenker, MD, FRCP (C), FAAN

Professor of neurology and consultant in neurology
Mayo Clinic
Rochester, Minnesota


Declaration of accreditation of physicians

Paradigm Medical Communications, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education to physicians.

Credit designation

Physician credit designation statement
Paradigm Medical Communications, LLC designates this durable material to a maximum of 1.0 AMA PRA Category 1 credit™. Physicians should only claim credit for the extent of their participation in the activity.

PA continuing education

PAs can claim a maximum of 1.0 Category 1 credit for completing this activity. NCCPA accepts AMA PRA Category 1 credit™ organizations accredited by ACCME or a recognized state medical society.

Continuing education as a nurse practitioner

The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of attendance for certified educational activities for AMA PRA Category 1 credit™ from organizations accredited by ACCME. Individuals are responsible for checking with AANPCP for further guidance.

How to participate in this activity and get CME credit

To receive a CME certificate of participation, you must:

  • Follow the instructions to register or log in with your business information and complete the pre-activity assessment
  • See the entire online activity
  • Complete and submit the post-test and assessment online. You must answer 70% of the post-test questions correctly to get credit. You will have unlimited opportunities to pass the post-test

A certificate of attendance will be available for download / print immediately upon successful completion of the post-test and assessment.

For any questions regarding CME credit, contact the Paradigm CME department at (845) 398-5949 or [email protected]

There is no fee required to participate in this activity.


In accordance with ACCME’s disclosure requirements, faculty and contributors are encouraged to disclose any relationship with business interests associated with the field of medicine featured in the activity. These relationships are described below. All potential conflicts of interest have been resolved.


Andrew Lee, MD
No relevant financial relationship to disclose.

Brian Gary Weinshenker, MD, FRCP (C), FAAN
Royalties: RSR limited
Patents / Intellectual Property Rights: NMO-IgG
Consultation fees: Chugai Pharmaceutical Co., Ltd .; F. Hoffmann-La Roche SA; Genentech, Inc .; Mitsubishi Tanabe Pharma Corporation; UCB, Inc.
Speakers Bureau: Genentech, Inc .; F. Hoffman-La Roche SA; Novartis
Selection committees: Alexion Pharmaceuticals, Inc .; Viela Bio, Inc.

Paradigm Medical Communications, LLC staff members do not have any financial relationships to disclose.

Independent peer reviewer

The Independent Reviewer has no financial relationship to disclose.

Conflict of Interest Resolution

Paradigm Medical Communications, LLC has a system in place to resolve conflicts of interest for each CME activity to ensure that the content is objective, fair and balanced, independent, and in the public interest. Conflicts, if any, are resolved by one or more processes. All of FMC’s content in this activity has been independently reviewed to ensure that it is free from commercial bias, scientifically rigorous, aligned with the public interest, and in compliance with all regulatory guidelines and Standards for Business Support of Continuing Medical Education.

Unlabelled and investigative use

This educational activity may contain a discussion of published and / or experimental uses of agents that are not approved by the Food and Drug Administration (FDA).


This CME activity represents the views and opinions of each faculty and does not constitute the opinion, endorsement or promotion of Paradigm Medical Communications, LLC. Reasonable efforts have been made to present educational materials in a balanced, impartial manner and in accordance with regulatory requirements. However, each participant in the activity should always use their own personal and professional judgment when considering the further application of this information, especially with regard to patient diagnostic or treatment decisions, including, not limited to FDA approved uses and any off-label uses. .

If included, signed statements of informed consent granting permission to post have been obtained for all photographs and videos in which a person can be identified.

As an ACCME Accredited Provider, Paradigm Medical Communications, LLC’s business must include a balanced view of treatment options. The use of generic names contributes to this impartiality. The use of trade names should not be construed as an endorsement of specific products by Paradigm Medical Communications, LLC.

Copyright statement

© 2021 Paradigm Medical Communications, LLC, unless otherwise noted. Content may not be reproduced in whole or in part without the express written permission of Paradigm Medical Communications, LLC.

FMC Questions?

If you have any questions or comments, please email us at [email protected]

Leave A Reply

Your email address will not be published.